<i>Ex vivo</i> drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically-Reference-Cited by-同舟云学术

Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically

Published:2022-03 Issue:6 Volume:16 Page:1241-1258
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Molecular Oncology

Author:

Giliberto Mariaserena¹²³,Thimiri Govinda Raj Deepak B.¹²³,Cremaschi Andrea³⁴,Skånland Sigrid S.¹²³^ORCID,Gade Alexandra³,Tjønnfjord Geir E.²⁵,Schjesvold Fredrik²⁵⁶,Munthe Ludvig A.²⁶,Taskén Kjetil¹²³^ORCID

Affiliation:

1. Department of Cancer Immunology Institute for Cancer Research Oslo University Hospital Norway

2. K.G. Jebsen Centre for B Cell Malignancies Institute of Clinical Medicine University of Oslo Norway

3. Centre for Molecular Medicine Norway Nordic EMBL Partnership University of Oslo Norway

4. Oslo Centre for Biostatistics and Epidemiology University of Oslo Norway

5. Department of Haematology and Oslo Myeloma Centre Oslo University Hospital Norway

6. Department of Immunology and Transfusion Medicine Oslo University Hospital Norway

Funder

Universitetet i Oslo

Stiftelsen Kristian Gerhard Jebsen

Norges Forskningsråd

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.13191

Reference51 articles.

1. Multiple myeloma

2. Multiple myeloma: Every year a new standard?

3. Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response

4. Clonal competition with alternating dominance in multiple myeloma

5. “Direct to Drug” screening as a precision medicine tool in multiple myeloma

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Standardized assays to monitor drug sensitivity in hematologic cancers;Cell Death Discovery;2023-12-01

2. Dinaciclib synergizes with BH3 mimetics targeting BCL‐2 and BCL‐X_L in multiple myeloma cell lines partially dependent on MCL‐1 and in plasma cells from patients;Molecular Oncology;2023-09-28

3. Selinexor: Targeting a novel pathway in multiple myeloma;eJHaem;2023-05-15

4. Phenotypic deconvolution in heterogeneous cancer cell populations using drug-screening data;Cell Reports Methods;2023-03

5. A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma;Future Oncology;2023-01